In today’s ACT Brief, we examine how SCOPE 2026 reinforced the link between speed and strategy, how AI adoption is driving real-world efficiency gains, and how FDA’s evolving evidence standards could ...

While there are shared principles across development programs, Barr noted that the nuances within immunology, ophthalmology, or chronic care studies can determine whether a trial succeeds or fails.

Sponsors that proactively standardized data, adopted practical AI tools, and experimented responsibly, she noted, were already seeing measurable gains in efficiency and competitiveness. Editor's note: ...

In today’s ACT Brief, we examine how predictive analytics are shaping portfolio decisions, how industry collaboration is ...

FDA is shifting its default standard for drug approvals, announcing that one adequate and well-controlled clinical trial will generally be sufficient for approvals. FDA is expected to drop its ...

TransCelerate BioPharma has released its 2025 annual report, titled The Power of Forward, outlining a year defined by continued digital adoption, regulatory collaboration, and expansion of pragmatic ...

Zubel: In terms of analytics and AI, faster clinical data monitoring is already achievable. Predictive modeling is improving, but accuracy remains a challenge, particularly in oncology.

In today’s ACT Brief, we examine how AI is enabling continuous trial monitoring and faster site decisions, how provider ...

Findings from the VA’s Diuretic Comparison Project show pragmatic trial designs can achieve strong provider participation when burden is minimized and patient care remains the primary focus.